📊 BGLC Key Takeaways
Is BioNexus Gene Lab Corp (BGLC) a Good Investment?
BioNexus Gene Lab Corp is operating at pre-revenue scale with only $22.8K in declining revenue while burning $147.7K annually in operations. The company exhibits unsustainable economics with negative gross margins (-3.5%) and operating margins (-2366.2%), indicating severe operational distress with no visible path to profitability. Despite holding $1.3M in cash, current burn rates suggest critical liquidity challenges within 12-24 months absent significant revenue acceleration.
BioNexus Gene Lab Corp shows weak fundamentals driven by low gross profitability, deeply negative operating and net margins, and significant free cash flow burn relative to revenue. While the balance sheet is clean with high liquidity, no meaningful leverage, and positive equity, the business currently lacks evidence of durable earnings power or efficient growth. Unless margins improve materially and operating cash burn narrows, the financial profile remains high risk.
BioNexus Gene Lab Corp Key Strengths (BGLC)
- Zero long-term debt eliminates refinancing and default risk
- Liquidity ratio of 6.52x provides near-term operational cushion
- Positive stockholders equity of $8.1M provides balance sheet foundation
- Strong liquidity with an 8.30x current ratio and 6.81x quick ratio
- Debt-free balance sheet with minimal liabilities relative to equity
- Positive stockholders' equity of $6.82M provides balance sheet cushion
BGLC Stock Risks: BioNexus Gene Lab Corp Investment Risks
- Operating cash burn of $147.7K annually with only $1.3M cash reserves creates 8-12 month runway
- Revenue declining 21.9% YoY on minuscule $22.8K base signals failed commercialization
- Negative gross margins (-3.5%) indicate unit economics are fundamentally broken, not just scale issues
- No insider transactions in 90 days suggests management may lack confidence in recovery
- Gross margin of 15.7% is thin for supporting fixed costs, contributing to a -27.8% operating margin
- Operating cash flow of -$2.80M and free cash flow of -$2.84M indicate unsustainable cash burn without improvement
- Net losses and negative returns on equity and assets suggest weak growth quality and poor capital efficiency
Key Metrics to Watch
- Quarterly revenue trend and absolute revenue level for commercialization progress
- Operating cash flow burn rate relative to cash reserves depletion timeline
- Gross margin trajectory toward positive territory indicating operational viability
- Gross margin and operating margin trend
- Operating cash flow burn relative to revenue
BioNexus Gene Lab Corp (BGLC) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 6.52x current ratio provides a solid financial cushion.
BGLC Profit Margin, ROE & Profitability Analysis
BGLC vs Healthcare Sector: How BioNexus Gene Lab Corp Compares
How BioNexus Gene Lab Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is BioNexus Gene Lab Corp Stock Overvalued? BGLC Valuation Analysis 2026
Based on fundamental analysis, BioNexus Gene Lab Corp has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
BioNexus Gene Lab Corp Balance Sheet: BGLC Debt, Cash & Liquidity
BGLC Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: BioNexus Gene Lab Corp's revenue has declined by 29% over the 5-year period, indicating business contraction. The most recent EPS of $-0.17 indicates the company is currently unprofitable.
BGLC Revenue Growth, EPS Growth & YoY Performance
BGLC Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $22.8K | -$543.6K | $-0.23 |
| Q3 2025 | $2.5M | -$709.0K | $-0.40 |
| Q2 2025 | $2.0M | $95.3K | $0.05 |
| Q1 2025 | $2.1M | -$103.8K | $-0.01 |
| Q3 2024 | $2.6M | -$69.1K | N/A |
| Q2 2024 | $2.0M | -$69.1K | N/A |
| Q1 2024 | $2.4M | -$69.1K | N/A |
| Q2 2023 | $2.5M | $17.1K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BioNexus Gene Lab Corp Dividends, Buybacks & Capital Allocation
BGLC SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for BioNexus Gene Lab Corp (CIK: 0001737523)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BGLC
What is the AI rating for BGLC?
BioNexus Gene Lab Corp (BGLC) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 82% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BGLC's key strengths?
Claude: Zero long-term debt eliminates refinancing and default risk. Liquidity ratio of 6.52x provides near-term operational cushion. ChatGPT: Strong liquidity with an 8.30x current ratio and 6.81x quick ratio. Debt-free balance sheet with minimal liabilities relative to equity.
What are the risks of investing in BGLC?
Claude: Operating cash burn of $147.7K annually with only $1.3M cash reserves creates 8-12 month runway. Revenue declining 21.9% YoY on minuscule $22.8K base signals failed commercialization. ChatGPT: Gross margin of 15.7% is thin for supporting fixed costs, contributing to a -27.8% operating margin. Operating cash flow of -$2.80M and free cash flow of -$2.84M indicate unsustainable cash burn without improvement.
What is BGLC's revenue and growth?
BioNexus Gene Lab Corp reported revenue of $22.8K.
Does BGLC pay dividends?
BioNexus Gene Lab Corp does not currently pay dividends.
Where can I find BGLC SEC filings?
Official SEC filings for BioNexus Gene Lab Corp (CIK: 0001737523) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BGLC's EPS?
BioNexus Gene Lab Corp has a diluted EPS of $-0.23.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is BGLC's fundamental grade?
Based on our AI fundamental analysis in June 2026, BioNexus Gene Lab Corp has a D grade with 82% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is BGLC stock overvalued or undervalued?
Valuation metrics for BGLC: ROE of -6.7% (sector avg: 15%), net margin of -2,379.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is BGLC's AI grade for 2026?
Our dual AI analysis gives BioNexus Gene Lab Corp a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BGLC's free cash flow?
BioNexus Gene Lab Corp's operating cash flow is $-147.7K, with capital expenditures of $325.0. FCF margin is -647.9%.
How does BGLC compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -2,379.7% (avg: 12%), ROE -6.7% (avg: 15%), current ratio 6.52 (avg: 2).